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Epithelial-to-mesenchymal transition in a fistula-associated
anal adenocarcinoma in a patient with long-standing
Crohn’s disease
Michael Scharla, Pascal Freia, Sandra M. Freia, Luc Biedermanna,
Achim Weberb and Gerhard Roglera
Anal adenocarcinomas arising from perianal fistulae
represent a rare complication in Crohn’s disease (CD)
patients. We have previously demonstrated the
involvement of an epithelial-to-mesenchymal transition
(EMT) in the pathogenesis of CD-associated fistulae.
Although EMT has also been implicated in the
development of colorectal and anal carcinoma, the
molecular link from fistula to carcinoma is unclear.
We present a case of a 48-year-old White woman who
developed a mucinous anal adenocarcinoma originating
from a perianal, CD-associated fistula 24 years after
being diagnosed with CD. To characterize the expression
of EMT-associated molecules in fistula and carcinoma
tissue, immunohistochemical analysis for Snail1, Slug,
b-catenin and E-cadherin was performed. A mucinous
anal adenocarcinoma developed on a perianal fistula
in a patient with long-standing CD. After neoadjuvant
radiochemotherapy, the fistula-associated tumour was
resected and the patient is presently in remission. Using
immunohistochemical analysis, we detected a remarkable
staining of the Slug transcription factor in transitional cells
lining the fistula tract. This observation is unique to this
‘carcinoma’-fistula: we had previously shown Slug
expression in cells surrounding the fistula tract but not
in transitional cells. Expression of Snail1, b-catenin and
E-cadherin in this case was comparable with our previous
findings. We describe a rare case of a CD fistula-associated
adenocarcinoma within an area of squamous epithelium of
the perianal area and an unusual expression pattern of
EMT markers in this fistula. This case seems to underline
the relevance of our previous findings demonstrating that
EMT plays an important role for fistula pathogenesis and
likely carcinogenesis in CD patients. Eur J Gastroenterol
Hepatol 26:114–118 c 2013 Wolters Kluwer Health |
Lippincott Williams & Wilkins.
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Introduction
Crohn’s disease (CD), a subtype of inflammatory bowel
disease, is characterized by a chronic and transmural
inflammation of the gastrointestinal (GI) tract. One of its
most important complications is the development of CD-
associated fistulae that can occur anywhere along the GI
tract. According to population-based cohorts, the cumu-
lative incidence of fistulas in CD patients is 17–50%. The
most frequent fistulas are perianal (54%), enteroenteric
(24%) and rectovaginal (9%) [1]. However, fistulae
represent a recurring complication in about one-third of
affected patients, making them difficult to treat.
Although new and more effective medications, such as
antitumour necrosis factor (anti-TNF) antibodies, have
been developed for inflammatory bowel disease and CD
in particular, the outcome of medical fistula therapy is
still poor and surgery is often needed [2,3].
A rare complication of CD is represented by carcinomas
arising from perianal fistulas, in particular anal adenocarcino-
ma. Such adenocarcinomas develop in an area of squamous
epithelia such as the perineum. As CD fistula tracts are
either covered by squamous cells or flat cells – attributed as
‘mesenchymal cells’ until we identified them as epithelial-to-
mesenchymal transition (EMT)-transformed intestinal
epithelial cells (IECs) – the origin of the adenocarcinoma
cells on the skin surface was so far unclear. To date, less than
70 cases of CD fistula-associated adenocarcinomas have been
described in the literature [4]. The presence of such CD-
associated anal adenocarcinomas is clearly associated with
long-standing perianal fistulizing disease [5]. The outcome
for patients with fistula-associated anal adenocarcinoma is
generally poor, especially in patients with node-positive
carcinoma, featuring an overall survival rate of 54% [4]. Here,
we report the case of a 48-year-old White woman suffering
from severe fistulizing CD who developed a mucinous
adenocarcinoma of the anus originating from a CD-associated
fistula tract 24 years after being diagnosed with CD.
Case report
In December 2009, a 45-year-old female patient was
referred to our outpatient clinic as she had active, severe,
fistulising CD with persistent massive abdominal pain
114 Case report
0954-691X c 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins DOI: 10.1097/MEG.0b013e32836371a2
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
and a perianal fistula despite a 10-month treatment with
certolizumab pegol.
The patient had first been diagnosed with CD in 1985 at
the age of 20. In 1986, an ileocoecal resection was
performed as stenosis of the ileum was observed. In 1993,
a perianal abscess accompanied by a rectovaginal fistula
occurred, and in 1998 it was finally surgically removed
owing to the ongoing complications. Because a stenosis
was present in the area of the ileoascendostomy, a follow-
up resection had to be performed. From 2002 to 2006, the
patient suffered from recurrent episodes of severe pain in
the epigastric region, along with nausea, vomitus and
diarrhoea. Finally, in March 2006, a capsule endoscopy
was performed, which revealed severe inflammation and
stenosis in the small intestine. Consequently, the
immunosuppressive medication was switched from
6-mercaptopurin to methotrexate (MTX). As the patient
began suffering from even more abdominal pain after the
injections, MTX was stopped in November 2006, and
therapy with infliximab was initiated in January 2007. In
the following months, the perianal fistulas partially
declined; however, the severe abdominal pain was
persistent, and in October 2007 infliximab was finally
stopped. In autumn 2008, an acute flare of CD was
successfully treated with budesonide administered orally.
Nevertheless, as the abdominal pain became even worse,
in February 2009, a second anti-TNF therapy was started
with certolizumab pegol. However, the abdominal pain
and perianal fistulas remained unaltered.
On initial presentation at our outpatient clinic, we
detected an acute CD flare in the region of the terminal
ileum with a bowel wall thickening of up to 8mm
determined ultrasonographically and decided to switch
therapy to adalimumab as a third anti-TNF medication.
In the following months, the abdominal pain clearly
improved, but diarrhoea was still persistent to some
extent; additional therapy with budesonide was started
finally, which caused normalization of stool consistency
within 6 months after start of adalimumab. As the
complaints from the perianal fistulae still persisted,
antibiotic treatment with ciprofloxacin and metronidazole
was started.
In February 2010, a small perianal tumour in the fistula
region was seen and biopsied. Histopathological assess-
ment revealed a florid erosion and ulceration next to a
chronically granulating inflammation with embedded
excavations that were lined with cubic and cylindrical
epithelium. No malignant cells were detected. As the
swelling progressed, in July 2010, an MRI of the pelvis
was performed; a complex fistula system with a perianal
tumour on the right side with a size of 3.8 2.3 3.5 cm
Fig. 1
Fistula-associated perianal adenocarcinoma. The tumour has been shown (a) macroscopically, (b) by means of colonoscopy (blue arrow points onto
the fistula opening), (c) by endosonography and (d) by MRI scan.
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was thus detected. From the tumour, a fistula was growing
towards the anal part of the rectum (Fig. 1). An additional
biopsy was performed. Histopathological assessment
revealed that the tumour was a poorly differentiated
mucinous adenocarcinoma of the anus arising from the
fistula tract. On the PET-CTscan, no lymph node or solid
organ metastases were detected; endosonography re-
vealed a connection of the tumour to a transsphincteric
fistula and tumour infiltration into the subcutis. Adali-
mumab was continued. Neoadjuvant radiochemotherapy
was performed in August/September 2010. Radiotherapy
of the primary tumour consisted of 25 sessions applying
1.8Gy each, accompanied by concomitant chemotherapy
with 5-fluoruracil, which was poorly tolerated. In the
following weeks, an acute Crohn’s flare occurred, which
could be confirmed by MRI, endoscopy and histopatho-
logical assessment. The tumour lesion was smaller in size.
In November 2010, amputation of the rectum was
performed. The tumour stage was finally determined to
be ypT2, ypN0 (0/14), cM0, R0, and the tumour was
proved histopathologically as a mucinous adenocarcinoma
of the perineum. Adalimumab was preoperatively stopped
and suspended because of an increased risk of infectious
complications during surgery and the potential effect
on the development of malignancies. Budesonide was
continued. In January 2011, an acute CD flare was sono-
graphically diagnosed, treatment with MTX was
reinitiated; this time it was well tolerated, and the health
condition improved. However, the patient again pre-
sented with abdominal pain and radiological signs of a
subileus due to a structuring lesion observed at ileocoe-
costomy, which was finally resected in November 2011.
Since then, the patient is fairly stable and in good
condition; she is under therapy with intermittent
budesonide courses. Anti-TNF medication has not been
resumed. To date, no relapse of the anal carcinoma was
observed.
Discussion
In our case, a fistula-associated mucinous adenocarcinoma
of the perineum arose in a patient suffering from CD for
25 years. Although mainly patients with ulcerative colitis
are regarded to be at increased risk for developing
colorectal cancer, the relative risk for CD patients to
develop small bowel cancer is 28.4-fold and that of
colorectal cancer is 2.4-fold higher compared with the
normal population [6]. There is a significant association
between the site of inflammation within the GI tract and
the risk of cancer in the respective part as well as
between the duration of CD and the cancer risk [6,7].
Chronically ongoing fistulizing inflammation carries an
elevated risk of malignant transformation, regardless of
the anatomical location [8]. The average patient devel-
oping a CD fistula-associated carcinoma would have been
suffering from CD for 24 years, from perianal fistulas
for 14 years and from perianal disease for at least 10
years [4]. The majority of patients seem to be female
(57%; mean age: 53 years). Our 45-year-old patient might
thus be a ‘typical’ patient suffering from CD for 24 years
with a history of perianal, fistulizing disease of more than
15 years. Her perianal fistulas were extensively treated
but were recurrent after surgery, not responding to any
medical treatment, and featured throughout signs of
inflammation such as abscesses and pain, which are also
the most common symptoms of the patients reported in
the literature [4].
In our case, an initial biopsy of the suspicious region was
performed; however, no signs of malignancy were
detected, and no malignancy was suspected even by
MRI. It has thus been shown that biopsies and
preoperative imaging results can be false negative in
many patients [4]. The carcinoma in our patient was
detected at an early T2 stage with no lymph node or solid
organ metastasis. This seems to be unusual, as in the
report of Iesalnieks et al. [4], about 95% of patients had a
T3 or even a T4 stage at the time of diagnosis, 50% of
whom had documented inguinal lymph node involvement
and about 10% presented with distant organ metastasis.
Prognosis of CD patients with fistula-associated anal
adenocarcinoma is poor. In about 55% of all patients,
tumour recurrence occurs after abdominoperineal resec-
tion (APR), following a mean duration of 16.6 (2–55)
months. Tumour recurrence was observed in 14 of 15
lymph node-positive patients; a positive nodal status is
found to be significantly associated with poor outcomes
after APR on multivariate analysis [4]. The overall
survival rate after APR is 88% at 1 year, 54% at 2 years
and 26% at 5 years. Our patient remains tumour-free after
about 24 months following APR.
We have previously described that an EMT plays a key
role in the pathogenesis of CD-associated fistulae and
that EMT-associated molecules, namely, Snail1, Slug,
b-catenin and E-cadherin feature a unique expression
pattern along the tracts of CD-associated fistulae [9–12].
Interestingly, EMT is also critically involved in the
pathogenesis of colorectal and anal carcinoma, and
the onset of EMT is a bad prognostic factor [13,14].
To assess a possible involvement of EMT-related events
in the pathogenesis of the described CD fistula-
associated anal adenocarcinoma, we immunohistochemi-
cally stained tissue specimens of the fistula as well as of
the carcinoma. These tissue samples were obtained
before any therapeutic intervention was performed. The
Snail1 transcription factor, a known mediator of EMT, was
clearly detectable in the nuclei of myofibroblast-like
mesenchymal cells, the so-called transitional cells (TCs),
lining the fistula tract in our patient. This is in good
accordance with our previous observations [11]. In
addition, nuclear, meaning activated, Snail1 protein is
detectable in most of the tumour cells (Fig. 2a). However,
the Slug transcription factor, which is also associated with
116 European Journal of Gastroenterology & Hepatology 2014, Vol 26 No 1
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
the onset of EMT, was clearly detected in TCs and in
cells below the fistula surface. This is in contrast to our
previous observations, as to date we had detected Slug
expression only in cells below the surface epithelium
but not in TCs [11]. In the carcinoma cells, Slug was
strongly detectable (Fig. 2b). Strong staining for b-catenin
was detected in IECs along the fistula tract, mainly at the
lateral cell membrane. According to our previous observa-
tions [10], b-catenin staining was clearly less intense in
TCs. With regard to the carcinoma, membrane staining of
b-catenin was visible in IECs; however, a large number of
tumour cells also revealed nuclear staining of the
transcription factor (Fig. 2c) [10]. Similarly, the epithelial
protein E-cadherin was also strongly detectable at the
membrane of cylindrical IECs along fistula tracts but TCs
were clearly less stained, which is in good accordance
with our previous findings [10]. However, E-cadherin was
strongly detectable in IECs in the carcinoma tissue
(Fig. 2d).
These observations confirm our previous findings on the
expression of EMT-associated proteins along or around
CD-associated fistulae [10–12]. Of note, the Slug
transcription factor was also expressed in the TC lining
the fistula in this patient, whereas we had previously only
found Slug staining in cell layers below the fistula surface.
This observation might be because of the carcinoma
originating from TCs of the fistula, as Slug expression is
also associated with tumour progression. These findings
in a patient with fistula-associated mucinous adenocarci-
noma of the perianal/perineal region seem to support our
previous findings on the expression of EMT-associated
proteins in CD-associated fistulas.
Conclusion
Although fistula-associated anal carcinoma is a rare
occurrence, this case highlights that chronic fistulizing
CD should be considered as precancerosis. A high index
of suspicion for malignancy is mandatory in the case of a
suspicious perianal or distal rectal mass lesion, even in the
absence of malignant cells on histological analysis. More-
over, this case once more envisions that sufficient
treatment options for refractory fistulizing CD are still a
largely unmet need for a substantial fraction of CD
patients.
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